Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data

Does preexisting or treatment-emergent autoimmunity increase the risk of subsequent autoimmune disease in individuals with relapsing-remitting multiple sclerosis (MS) after alemtuzumab? In the extended phase 2/3 trials, 34/96 (35.4%) patients with and 395/1120 (35.3%) without preexisting autoimmunit...

Descripción completa

Detalles Bibliográficos
Autores principales: Coles, Alasdair J, Jones, Joanne L, Vermersch, Patrick, Traboulsee, Anthony, Bass, Ann D, Boster, Aaron, Chan, Andrew, Comi, Giancarlo, Fernández, Óscar, Giovannoni, Gavin, Kubala Havrdova, Eva, LaGanke, Christopher, Montalban, Xavier, Oreja-Guevara, Celia, Piehl, Fredrik, Wiendl, Heinz, Ziemssen, Tjalf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978465/
https://www.ncbi.nlm.nih.gov/pubmed/34882037
http://dx.doi.org/10.1177/13524585211061335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978465/
https://www.ncbi.nlm.nih.gov/pubmed/34882037
http://dx.doi.org/10.1177/13524585211061335

Ejemplares similares